A detailed history of Fifth Third Bancorp transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Fifth Third Bancorp holds 832 shares of ARWR stock, worth $20,983. This represents 0.0% of its overall portfolio holdings.

Number of Shares
832
Previous 1,162 28.4%
Holding current value
$20,983
Previous $35,000 34.29%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$27.21 - $39.48 $8,979 - $13,028
-330 Reduced 28.4%
832 $23,000
Q4 2023

Jan 19, 2024

BUY
$21.2 - $31.03 $3,688 - $5,399
174 Added 17.61%
1,162 $35,000
Q3 2023

Oct 31, 2023

BUY
$26.2 - $36.08 $13,676 - $18,833
522 Added 112.02%
988 $26,000
Q2 2023

Jul 25, 2023

BUY
$25.16 - $41.38 $8,202 - $13,489
326 Added 232.86%
466 $16,000
Q1 2023

Apr 24, 2023

SELL
$23.68 - $38.51 $4,807 - $7,817
-203 Reduced 59.18%
140 $3,000
Q4 2022

Jan 25, 2023

SELL
$28.0 - $40.56 $2,100 - $3,042
-75 Reduced 17.94%
343 $0
Q3 2022

Oct 25, 2022

SELL
$29.63 - $48.31 $4,000 - $6,521
-135 Reduced 24.41%
418 $14,000
Q2 2022

Aug 04, 2022

BUY
$27.79 - $50.61 $9,393 - $17,106
338 Added 157.21%
553 $19,000
Q1 2022

Apr 19, 2022

SELL
$39.62 - $69.97 $8,795 - $15,533
-222 Reduced 50.8%
215 $10,000
Q4 2021

Feb 01, 2022

BUY
$58.09 - $82.51 $7,609 - $10,808
131 Added 42.81%
437 $29,000
Q3 2021

Oct 15, 2021

BUY
$58.38 - $84.96 $7,939 - $11,554
136 Added 80.0%
306 $19,000
Q2 2021

Aug 06, 2021

BUY
$62.15 - $90.32 $2,486 - $3,612
40 Added 30.77%
170 $14,000
Q1 2021

May 07, 2021

SELL
$61.35 - $90.47 $306 - $452
-5 Reduced 3.7%
130 $9,000
Q4 2020

Feb 16, 2021

BUY
$43.82 - $85.37 $4,820 - $9,390
110 Added 440.0%
135 $10,000
Q3 2020

Nov 09, 2020

BUY
$33.21 - $51.27 $830 - $1,281
25 New
25 $1,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.67B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Fifth Third Bancorp Portfolio

Follow Fifth Third Bancorp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.